Literature DB >> 2565752

GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.

M Hadjiconstantinou1, A P Mariani, N H Neff.   

Abstract

The administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice results in the loss of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) from the mouse striatum and a loss of cells containing tyrosine hydroxylase (TH)-immunoreactivity from the substantia nigra. The cells that remained in the nigra after MPTP treatment were smaller in diameter than normal cells. Treatment with GM1 ganglioside beginning 24 h after establishing the MPTP lesion resulted in partial restoration of DA and DOPAC content in the striatum and an increase in the diameter of the TH-immunoreactive nigra cells. It appears, therefore, that treatment of MPTP-intoxicated mice with GM1 ganglioside results in the partial restoration of both the biochemistry and morphology of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565752     DOI: 10.1016/0006-8993(89)90373-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

Review 1.  A scientific rationale for protective therapy in Parkinson's disease.

Authors:  C W Olanow
Journal:  J Neural Transm Gen Sect       Date:  1993

2.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

3.  Targeted deletion of GD3 synthase protects against MPTP-induced neurodegeneration.

Authors:  Y Akkhawattanangkul; P Maiti; Y Xue; D Aryal; W C Wetsel; D Hamilton; S C Fowler; M P McDonald
Journal:  Genes Brain Behav       Date:  2017-04-18       Impact factor: 3.449

4.  Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo.

Authors:  T Hagg; S Varon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

Review 5.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

6.  Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.

Authors:  K Fuxe; A M Janson; L Rosén; U B Finnman; S Tanganelli; M Morari; M Goldstein; L F Agnati
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

7.  Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies.

Authors:  Jianshe Wei; Masayo Fujita; Masaaki Nakai; Masaaki Waragai; Akio Sekigawa; Shuei Sugama; Takato Takenouchi; Eliezer Masliah; Makoto Hashimoto
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 8.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

9.  GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat.

Authors:  C K Meshul; R K Stallbaumer; C Allen
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

10.  Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease.

Authors:  Yu-Lin Guo; Wen-Jun Duan; Dan-Hua Lu; Xiao-Hui Ma; Xiao-Xiao Li; Zhao Li; Wei Bi; Hiroshi Kurihara; Hai-Zhi Liu; Yi-Fang Li; Rong-Rong He
Journal:  Acta Pharmacol Sin       Date:  2020-07-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.